Lobe Sciences Reports Q2 2026 Financials and Operational Progress

Lobe Sciences Ltd. has released its unaudited financial results for Q2 2026, ending February 28, 2026, along with an operational update. The Vancouver-based biopharmaceutical company reported cash assets of $1.07 million and short-term investments totaling over $3.88 million, underpinning its ongoing development initiatives. Net working capital stood at $2.16 million.

Research and development expenses rose significantly to $2.11 million, due to progress in its core programs - L-130 by Cynaptec Pharmaceuticals and S-100 by Applied Lipid Therapeutics. This increase in R&D investments contributed to a net loss of $3.69 million for the quarter compared to $1.50 million in the same period last year.

CEO Dr. Fred Sancilio noted the advancement of L-130 and S-100, measuring developments with disciplined capital management. A recent $950,000 private placement further supports Lobe’s strategic goals and development pipeline.